Effect of 3 months and 12 months of financial incentives on 12-month postpartum smoking cessation maintenance: A randomized controlled trial.
Abstinence
financial incentives
intervention
postpartum
pregnancy
randomized controlled trial
relapse
smoking
vouchers
Journal
Addiction (Abingdon, England)
ISSN: 1360-0443
Titre abrégé: Addiction
Pays: England
ID NLM: 9304118
Informations de publication
Date de publication:
16 Apr 2024
16 Apr 2024
Historique:
received:
20
11
2023
accepted:
22
02
2024
medline:
16
4
2024
pubmed:
16
4
2024
entrez:
16
4
2024
Statut:
aheadofprint
Résumé
Offering financial incentives is effective for smoking cessation during pregnancy. We tested the effectiveness of financial incentives for maintaining postpartum cessation, comparing 12-month and 3-month incentives with each other and with usual care (UC). This study was a pragmatic, multi-centre, three-arm randomized controlled trial involving four English, National Health Service, stop smoking services. A total of 462 postpartum women (aged ≥ 16 years) took part, who stopped smoking during pregnancy with financial incentives, validated as abstinent from smoking at end of pregnancy or early postpartum. Interventions comprised (i) UC; (ii) UC plus up to £60 of financial voucher incentives offered to participants and £60 offered to an optional significant-other supporter, over 3 months postpartum, contingent upon validated abstinence ('3-month incentives'); or (iii) UC plus '3-month incentives' plus £180 of vouchers offered to participants over 9 months postpartum, contingent upon abstinence ('12-month incentives'). Primary outcome: biochemically validated abstinence at 1 year postpartum. To adjust for testing all comparisons between groups with equal precision, P < 0.017 was necessary for significance. self-reported and validated abstinence at 3 months postpartum; self-reported abstinence at 1 year postpartum. Primary outcome ascertainment: abstinence was 39.6% (63/159) 12 months incentives, 21.4% (33/154) 3 months incentives and 28.2% (42/149) UC. Adjusted odds ratios [95% confidence interval (CI)] = 12-month versus 3-month incentives OR = 2.41 (95% CI = 1.46-3.96), P = 0.001; 12 months versus UC 1.67 (1.04-2.70), P = 0.035; 3 months versus UC 0.69 (0.41-1.17), P = 0.174. Bayes factors indicated that for 12-month versus 3-month incentives and 12 months versus UC there was good evidence for the alternative hypothesis, and for 3 months versus UC there was good evidence for the null hypothesis. This randomized controlled trial provides weak evidence that up to £300 of voucher incentives over 12 months is effective for maintaining smoking abstinence postpartum compared with usual care. There was good evidence that 12-month incentives are superior to those over only 3 months, for which there was no evidence of effectiveness relative to usual care.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Offering financial incentives is effective for smoking cessation during pregnancy. We tested the effectiveness of financial incentives for maintaining postpartum cessation, comparing 12-month and 3-month incentives with each other and with usual care (UC).
DESIGN, SETTING AND PARTICIPANTS
METHODS
This study was a pragmatic, multi-centre, three-arm randomized controlled trial involving four English, National Health Service, stop smoking services. A total of 462 postpartum women (aged ≥ 16 years) took part, who stopped smoking during pregnancy with financial incentives, validated as abstinent from smoking at end of pregnancy or early postpartum.
INTERVENTIONS
METHODS
Interventions comprised (i) UC; (ii) UC plus up to £60 of financial voucher incentives offered to participants and £60 offered to an optional significant-other supporter, over 3 months postpartum, contingent upon validated abstinence ('3-month incentives'); or (iii) UC plus '3-month incentives' plus £180 of vouchers offered to participants over 9 months postpartum, contingent upon abstinence ('12-month incentives').
MEASUREMENTS
METHODS
Primary outcome: biochemically validated abstinence at 1 year postpartum. To adjust for testing all comparisons between groups with equal precision, P < 0.017 was necessary for significance.
SECONDARY OUTCOMES
RESULTS
self-reported and validated abstinence at 3 months postpartum; self-reported abstinence at 1 year postpartum.
FINDINGS
RESULTS
Primary outcome ascertainment: abstinence was 39.6% (63/159) 12 months incentives, 21.4% (33/154) 3 months incentives and 28.2% (42/149) UC. Adjusted odds ratios [95% confidence interval (CI)] = 12-month versus 3-month incentives OR = 2.41 (95% CI = 1.46-3.96), P = 0.001; 12 months versus UC 1.67 (1.04-2.70), P = 0.035; 3 months versus UC 0.69 (0.41-1.17), P = 0.174. Bayes factors indicated that for 12-month versus 3-month incentives and 12 months versus UC there was good evidence for the alternative hypothesis, and for 3 months versus UC there was good evidence for the null hypothesis.
CONCLUSIONS
CONCLUSIONS
This randomized controlled trial provides weak evidence that up to £300 of voucher incentives over 12 months is effective for maintaining smoking abstinence postpartum compared with usual care. There was good evidence that 12-month incentives are superior to those over only 3 months, for which there was no evidence of effectiveness relative to usual care.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Greater Manchester Combined Authority
Informations de copyright
© 2024 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.
Références
Chamberlain C, O'Mara‐Eves A, Porter J, Coleman T, Perlen SM, Thomas J, et al. Cochrane Pregnancy and Childbirth Group. Psychosocial interventions for supporting women to stop smoking in pregnancy. Cochrane Database Syst Rev. 2017;2:CD001055.
Simmons VN, Sutton SK, Quinn GP, Meade CD, Brandon TH. Prepartum and postpartum predictors of smoking. Nicotine Tob Res. 2014;16:461–468.
Jones M, Lewis S, Parrott S, Wormall S, Coleman T. Re‐starting smoking in the postpartum period after receiving a smoking cessation intervention: a systematic review. Addiction. 2016;111:981–990.
Risch HA, Howe GR, Jain M, Burch JD, Holowaty EJ, Miller AB. Are female smokers at higher risk for lung cancer than male smokers? A case‐control analysis by histologic type. Am J Epidemiol. 1993;138:281–293.
Thun MJ, Carter BD, Feskanich D, Freedman ND, Prentice R, Lopez AD, et al. 50‐year trends in smoking‐related mortality in the United States. N Engl J Med. 2013;368:351–364.
Oberg M, Jaakkola MS, Woodward A, Peruga A, Prüss‐Ustün A. Worldwide burden of disease from exposure to second‐hand smoke: a retrospective analysis of data from 192 countries. Lancet. 2011;377:139–146.
Leonardi‐Bee J, Jere ML, Britton J. Exposure to parental and sibling smoking and the risk of smoking uptake in childhood and adolescence: a systematic review and meta‐analysis. Thorax. 2011;66:847–855.
Orton S, Coleman T, Coleman‐Haynes T, Ussher M. Predictors of postpartum return to smoking: a systematic review. Nicotine Tob Res. 2018;20:665–673.
Livingstone‐Banks J, Norris E, Hartmann‐Boyce J, West R, Jarvis M, Chubb E, et al. Cochrane Tobacco Addiction Group. Relapse prevention interventions for smoking cessation. Cochrane Database Syst Rev. 2019;10:CD003999.
Kock LS, Erath TG, Coleman SRM, Higgins ST, Heil SH. Contingency management interventions for abstinence from cigarette smoking in pregnancy and postpartum: a systematic review and meta‐analysis. Prev Med. 2023;31:107654.
National Institute of Health and Care Excellence, 2021. Tobacco: preventing uptake, promoting quitting and treating dependence. Recommendations on treating tobacco dependence in pregnant women. 2023. Available from: https://www.nice.org.uk/guidance/ng209/chapter/Recommendations-on-treating-tobacco-dependence-in-pregnant-women Accessed 13 Nov.
Too E, Hastie CE, McMeekin N, Lucas G, Tappin MD. Are financial incentives effective and cost‐effective in a ‘real life’ smoking cessation program for pregnant women? A phase IV ‘before and after’ study to provide evidence to secure long‐term funding. J Women's Health Reprod Med. 2021;5:17.
McMeekin N, Sinclair L, Robinson‐Smith L, Mitchell A, Bauld L, Tappin DM, et al. Financial incentives for quitting smoking in pregnancy: are they cost‐effective? Addiction. 2023;118:1445–1456.
Shepard DS, Slade EP, Nighbor TD, DeSarno MJ, Roemhildt ML, Williams RK, et al. Economic analysis of financial incentives for smoking cessation during pregnancy and postpartum. Prev Med. 2022;165:107079.
Tappin D, Sinclair L, Kee F, McFadden M, Robinson‐Smith L, Mitchell A, et al. Effect of financial voucher incentives provided with UK stop smoking services on the cessation of smoking in pregnant women (CPIT III): pragmatic, multicentre, single blinded, phase 3, randomised controlled trial. BMJ. 2022;379:e071522.
UK Government, 2023. Pregnant Women Will be Offered Financial Incentives to Help Them Quit Smoking [internet] [cited 2023 Apr 10]. Available from: https://www.gov.uk/government/news/smokers-urged-to-swap-cigarettes-for-vapes-in-world-first-scheme Accessed 13 Nov 2023.
Donatelle RJ, Prows SL, Champeau D, Hudson D. Randomised controlled trial using social support and financial incentives for high risk pregnant smokers: significant other supporter (SOS) program. Tob Control. 2000;9:III67–III69.
Heil SH, Higgins ST, Bernstein IM, Solomon LJ, Rogers RE, Thomas CS, et al. Effects of voucher‐based incentives on abstinence from cigarette smoking and fetal growth among pregnant women. Addiction. 2008;103:1009–1018.
Higgins ST, Washio Y, Lopez AA, Heil SH, Solomon LJ, Lynch ME, et al. Examining two different schedules of financial incentives for smoking cessation among pregnant women. Prev Med. 2014;68:51–57.
Higgins ST, Nighbor TD, Kurti AN, Heil SH, Slade EP, Shepard DS, et al. Randomized controlled trial examining the efficacy of adding financial incentives to best practices for smoking cessation among pregnant and newly postpartum women. Prev Med. 2022;165:107012.
Kurti AN, Nighbor TD, Tang K, Bolívar HA, Evemy CG, Skelly J, et al. Effect of smartphone‐based financial incentives on Peripartum smoking among pregnant individuals: a randomized clinical trial. JAMA Netw Open. 2022;5:e2211889.
Ussher M, Best C, Lewis S, McKell J, Coleman T, Cooper S, et al. Financial incentives for preventing postpartum return to smoking (FIPPS): study protocol for a three‐arm randomised controlled trial. Trials. 2021;22:512.
Wong HY, Subramaniyan M, Bullen C, Amer Siddiq AN, Danaee M, Yee A. The mobile‐phone‐based iCO™ Smokerlyzer®: comparison with the piCO+ Smokerlyzer® among smokers undergoing methadone‐maintained therapy. Tob Induc Dis. 2019;17:65.
Bailey BA. Using expired air carbon monoxide to determine smoking status during pregnancy: preliminary identification of an appropriately sensitive and specific cut‐point. Addict Behav. 2013;38:2547–2550.
Bauld L, Hackshaw L, Ferguson J, Coleman T, Taylor G, Salway R. Implementation of routine biochemical validation and an ‘opt out’ referral pathway for smoking cessation in pregnancy. Addiction. 2012;107:53–60.
West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction. 2005;100:299–303.
Benowitz NL, Bernert JT, Foulds J, Hecht SS, Jacob P, Jarvis MJ, et al. Biochemical verification of tobacco use and abstinence: 2019 update. Nicotine Tob Res. 2020;22:1086–1097.
von Weymarn LB, Thomson NM, Donny EC, Hatsukami DK, Murphy SE. Quantitation of the minor tobacco alkaloids nornicotine, anatabine, and anabasine in smokers' urine by high throughput liquid chromatography‐mass spectrometry. Chem Res Toxicol. 2016;29:390–397.
Tappin D, Bauld L, Purves D, Boyd K, Sinclair L, MacAskill S, et al. Financial incentives for smoking cessation in pregnancy: randomised controlled trial. BMJ. 2015;350:h134.
Dumville JC, Torgerson DJ, Hewitt CE. Reporting attrition in randomised controlled trials. BMJ. 2006;332:969–971.
Kahan BC, Morris TP. Reporting and analysis of trials using stratified randomisation in leading medical journals: review and reanalysis. BMJ. 2012;345:e5840.
European Medicines Agency. Guideline on multiplicity issues in clinical trials. 2016. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-multiplicity-issues-clinical-trials_en.pdf Accessed 13 Nov 2023.
Kahan BC, Jairath V, Doré CJ, Morris TP. The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies. Trials. 2014;15:139.
Murray D, Cox JL. Screening for depression during pregnancy with the Edinburgh depression scale (EDDS). J Reprod Infant Psychol. 1990;8:99–107.
Fergusson D, Aaron SD, Guyatt G, Hébert P. Post‐randomisation exclusions: the intention to treat principle and excluding patients from analysis. BMJ. 2002;325:652–654.
Johnston E, Bains M, Hunter A, Langley T. The impact of the COVID‐19 pandemic on smoking, vaping, and smoking cessation Services in the United Kingdom: a qualitative study. Nicotine Tob Res. 2023;25:339–344.
Bricca A, Swithenbank Z, Scott N, Treweek S, Johnston M, Black N, et al. Predictors of recruitment and retention in randomized controlled trials of behavioural smoking cessation interventions: a systematic review and meta‐regression analysis. Addiction. 2022;117:299–311.
Muehlemann N, Zhou T, Mukherjee R, Hossain MI, Roychoudhury S, Russek‐Cohen E. A tutorial on modern Bayesian methods in clinical trials. Ther Innov Regul Sci. 2023;57:402–416.
Breen RJ, Palmer MA, Frandsen M, Ferguson SG. Design of Financial Incentive Programs for smoking cessation: a discrete choice experiment. Nicotine Tob Res. 2022;24:1661–1668.
Notley C, Brown TJ, Bauld L, Clark AB, Duneclift S, Gilroy V, et al. BabyBreathe trial: protocol for a randomised controlled trial of a complex intervention to prevent postpartum return to smoking. BMJ Open. 2023;13:e076458.
Levine MD, Marcus MD. Do changes in mood and concerns about weight relate to smoking relapse in the postpartum period? Arch Womens’ Ment Health. 2004;7:155–166.
Notley C, Blyth A, Craig J, Edwards A, Holland R. Postpartum smoking relapse‐‐a thematic synthesis of qualitative studies. Addiction. 2015;110:1712–1723.